Nektar Therapeutics (NKTR)

• Market cap: $166M
• 1 day: -6.38%
• 5 days: -26.83%
• 1 month: -10.00%
• 3 months: -31.82%
• 6 months: -35.71%
• Year to date: -6.35%
• 1 year: 74.42%
• 5 years: -96.78%
• 10 years: -94.23%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Employees: 137

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

691% more call options, than puts

Call options by funds: $182K | Put options by funds: $23K

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

5% more capital invested

Capital invested by funds: $175M [Q2] → $184M (+$8.87M) [Q3]

4% more funds holding

Funds holding: 134 [Q2] → 139 (+5) [Q3]

6% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 35

0.34% more ownership

Funds ownership: 76.79% [Q2] → 77.13% (+0.34%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 344% upside
• Avg. target: $5.83 548% upside
• High target: $7 678% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Arthur He 30% 1-year accuracy 12 / 40 met price target	622% upside $6.50	Buy Reiterated	13 Jan 2025
B. Riley Securities Mayank Mamtani 26% 1-year accuracy 6 / 23 met price target	344% upside $4	Buy Initiated	8 Jan 2025
Piper Sandler Yasmeen Rahimi 39% 1-year accuracy 11 / 28 met price target	678% upside $7	Overweight Initiated	4 Nov 2024